Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study
Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration. The post Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study appeared first on GEN - Genetic Engineering and Biotechnology News .
Nightingale Health will run the measurements in its labs using Alamar’s NULISA platform to quantify hundreds of blood proteins in 80,000 UK Biobank samples, seeking early molecular signs of neurodegeneration. The post Alamar, Nightingale Health Team up on UK Biobank Neurodegeneration Protein Study appeared first on GEN - Genetic Engineering and Biotechnology News .
This is a summary of the story. Read the full article at GEN — Genetic Engineering & Biotechnology News ↗